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Abstract
Transmembrane TNF-a, a precursor of the soluble form of TNF-a, is expressed on activated macrophages
and lymphocytes as well as other cell types. After processing by TNF-a-converting enzyme (TACE), the
soluble form of TNF-a is cleaved from transmembrane TNF-a and mediates its biological activities through
binding to Types 1 and 2 TNF receptors (TNF-R1 and -R2) of remote tissues. Accumulating evidence
suggests that not only soluble TNF-a, but also transmembrane TNF-a is involved in the inflammatory
response. Transmembrane TNF-a acts as a bipolar molecule that transmits signals both as a ligand
and as a receptor in a cell-to-cell contact fashion. Transmembrane TNF-a on TNF-a-producing cells
binds to TNF-R1 and -R2, and transmits signals to the target cells as a ligand, whereas transmembrane
TNF-a also acts as a receptor that transmits outside-to-inside (reverse) signals back to the cells after
binding to its native receptors. Anti-TNF agents infliximab, adalimumab and etanercept bind to and neu-
tralize soluble TNF-a, but exert different effects on transmembrane TNF-a-expressing cells
(TNF-a-producing cells). In the clinical settings, these three anti-TNF agents are equally effective for
RA, but etanercept is not effective for granulomatous diseases. Moreover, infliximab induces granuloma-
tous infections more frequently than etanercept. Considering the important role of transmembrane TNF-a
in granulomatous inflammation, reviewing the biology of transmembrane TNF-a and its interaction with
anti-TNF agents will contribute to understanding the bases of differential clinical efficacy of these prom-
ising treatment modalities.
Key words: Cytokine, Tumour necrosis factor-a, TNF, Outside-to-inside signal, Transmembrane, Infliximab,
Etanercept, Adalimumab.
Introduction
TNF-a is a potent pro-inflammatory cytokine exerting
pleiotropic effects on various cell types and plays a critical
role in the pathogenesis of chronic inflammatory diseases,
such as RA [1, 2]. Accumulating evidence suggests that
not only soluble TNF-a, but also its precursor form, trans-
membrane TNF-a, is involved in the inflammatory
response. Transmembrane TNF-a exerts its biological
function in a cell-to-cell contact fashion, which is distinct
from the feature of soluble TNF-a, which acts at sites
remote from the TNF-a-producing cells [3]. In transgenic
mice, transmembrane TNF-a was shown to be sufficient
to induce arthritis with synovial hyperplasia and inflamma-
tion [4, 5].
Transmembrane TNF-a acts as a ligand by binding to
TNF-a receptors as well as functioning as a receptor that
transmits outside-to-inside (reverse) signals back into
the transmembrane TNF-a-bearing cells (TNF-a-
producing cells) [6]. It is therefore considered that
transmembrane TNF-a plays a critical role in local inflam-
mation [7–10]. Anti-TNF agents have been successfully
introduced for the treatment of chronic inflammatory dis-
eases. However, clinical features against granulomatous
inflammation are not similar among these agents. For
example, all the anti-TNF agents are effective against
RA, but not all of them against Crohn’s disease [1, 2].
The binding and neutralizing activities against soluble
TNF-a are the critical and common mechanisms of
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Waction of these anti-TNF-agents. On the other hand,
recent studies have shown that these agents have differ-
ential effects against transmembrane TNF-a and
TNF-a-producing cells [7–10]. In the light of a growing
body of evidence for the involvement of transmembrane
TNF-a in inflammation, such as granulomatous inflamma-
tion, it would be important to summarize the biology of
transmembrane TNF-a in health and disease as well as
its interaction with anti-TNF agents. We would like to
review the following issues: (i) biological function of trans-
membrane TNF-a as a ligand, (ii) biological function of
transmembrane TNF-a as a receptor and (iii) different
effects of anti-TNF agents on transmembrane
TNF-a-bearing cells (TNF-a-producing cells) that would
help to understand the different clinical effects of the
anti-TNF agents.
Biology of transmembrane TNF-a and
soluble TNF-a
TNF-a is generated as a precursor form called transmem-
brane TNF-a that is expressed as a cell surface type II
polypeptide consisting of 233 amino acid residues
(26kDa) on activated macrophages and lymphocytes as
well as other cell types [11–13] (Fig. 1). After being pro-
cessed by such metalloproteinases as TNF-a-converting
enzyme (TACE) between residues alanine
76 and valine
77,
the soluble form of TNF-a of 157 amino acid residues
(17kDa) is released and mediates its biological activities
through Type 1 and 2 TNF receptors (TNF-R1 also known
as TNFRSF1A, CD120a and TNF-R2 also known as
TNFRSF1B, CD120b, respectively) [14–17]. Soluble
TNF-a is a homotrimer of 17-kDa cleaved monomers
and transmembrane TNF-a also exists as a homotrimer
of 26-kDa uncleaved monomers [18]. Transmembrane
TNF-a also binds to TNF-R1 and -R2, but its biological
activities are supposed to be mediated mainly through
TNF-R2 [19]. Transmembrane TNF-a is palmitoylated at
a specific cysteine residue located just at the boundary
between the transmembrane and the cytoplasmic
domains [20]. In addition, serine residues of the intracel-
lular domain of transmembrane TNF-a are phosphorylated
[21]. These kinds of post-translational modification may
be important for the regulation of transmembrane TNF-a
function. After releasing soluble TNF-a by TACE cleavage,
the residual cytoplasmic domain of transmembrane TNF-a
migrated back into the nucleus of the transmembrane
TNF-a-bearing cells [22].
TNF-R1 and -R2 are expressed on almost all nucleated
cells [17] in the form of pre-assembled trimers [23]. Both
TNF receptors are capable of binding intracellular adaptor
proteins that lead to activation of complex intracellular
Fig. 1 Biology of transmembrane TNF-a and soluble TNF-a.
Transmembrane TNF-a is a precursor form of soluble TNF-a that is expressed on TNF-a-producing cells as a homotrimer.
After processing by TACE, soluble TNF-a is generated and binds to TNF-R1 or -R2. Transmembrane TNF-a also binds to
TNF-R1 and -R2. Upon binding to TNF receptors, both transmembrane and soluble TNF-a mediate pleiotropic effects
(apoptosis, cell proliferation and cytokine production). The remaining transmembrane TNF-a after cleavage with TACE is
further processed by SPPL2b and the intracellular domain is translocated into the nucleus and is supposed to mediate
cytokine production. tmTNF: transmembrane TNF-a; sTNF: soluble TNF-a.
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of TNF-a [2, 24]. The signalling pathways initiated by
TNF-R2, which may be the preferential receptor for trans-
membrane TNF-a, are less characterized compared with
those of TNF-R1. However, TNF-R2 appears to have both
shared and opposing effects to TNF-R1 and may be
actively involved in the pathogenesis of inflammatory dis-
eases [25]. Although controversial, a functional M196R
polymorphism of TNF-R2 [26] is associated with an
increased risk of a number of inflammatory diseases,
such as RA [27, 28], SLE [26, 29] and ulcerative colitis
[30]. A meta-analysis revealed the association of the
196R polymorphism of TNF-R2 and SLE [31].
Biological activities of transmembrane
TNF-a as a ligand
Transmembrane TNF-a on the cell surface of TNF-a-
producing cells binds to TNF receptors on the target
cells and exerts various biological functions that will con-
tribute to the modulation of local inflammation in a cell-to-
cell contact manner as well as in a cell-type-specific fash-
ion. Expression of transmembrane TNF-a on various cell
types would contribute to the physiological as well as
pathological responses in health and diseases (Table 1).
Cytotoxic activity
In the late 1980s, a number of reports showed the cyto-
toxic effects mediated by transmembrane TNF-a. Human
macrophages and lymphocytes stimulated with such
agents as lipopolysaccharide (LPS), IFN-g or phorbol myr-
istate acetate express transmembrane and soluble TNF-a.
Tumour cells were lysed by incubating with transmem-
brane TNF-a on paraformaldehyde-fixed activated mono-
cytes [32–34], paraformaldehyde-fixed activated
lymphocytes [33] and microsomes [12]. This cytotoxic
activity is mediated by TNF receptors [34]. Freshly
isolated human NK cells constitutively express
transmembrane TNF-a that mediates cytotoxic activity
[35]. In patients with HIV infection and acute respiratory
distress syndrome, functionally active, cytotoxic
transmembrane TNF-a was expressed on the alveolar
macrophages [36, 37], which is supposed to be a mech-
anism for TNF-a-mediated lung injury. CD8
+ T cells in SLE
patients express an increased amount of transmembrane
TNF-a upon activation and exerts cytotoxic activity
when incubated with L929 cells [38]. Monocytes
primed with cytokines demonstrated increased killing
of tumour cell lines as well as primary acute myeloid
leukaemia blasts by a mechanism dependent on trans-
membrane TNF-a [39]. In experimental Con A-induced
or melphalan-induced hepatitis [40, 41], transmembrane
TNF-a is involved in the pathogenesis through both
TNF-R1 and -R2. Melphalan inhibited TACE and induced
Kupffer cells to express transmembrane TNF-a, which
leads to hepatocyte injury. In endothelial programmed
cell death by ionizing radiation and LPS, transmembrane
TNF-a played a critical role through TNF-R1 [42]. Lipid
rafts participate in the cytotoxicity of transmembrane
TNF-a through intercellular adhesion molecule-1
(ICAM-1) clustering and consequent enhancement of the
cell-to-cell contact in Raji cells [43].
Hostdefence against intracellular pathogens
One of the major biological roles of TNF-a is in the host
defence to bacterial, viral and parasitic infections [2]. The
importance of transmembrane TNF-a in the inhibition of
intracellular organisms is beginning to be elucidated.
HIV-infected T-cell line or HIV-infected peripheral blood
lymphocytes were induced to cell death when co-cultured
with cells expressing transmembrane TNF-a through
cooperative signalling of TNF-R1 and -R2 [44]. The con-
tact mechanism mediated by transmembrane TNF-a
on CD4
+ T cells activated Leishmania major-infected
macrophages to inhibit the growth of intracellular
Leishmania, an effect it exerts more strongly than soluble
Table 1 Biological activities of transmembrane TNF-a as a ligand
Target Function References
Tumour cells (various types) Cytotoxicity [32–35, 38, 39, 43]
HIV-infected lymphocyte Cell death [44]
Intracellular parasite-infected macrophage Inhibit the growth of intracellular pathogens [45–49]
Mycobacterium infection T-cell and macrophage migration,
granuloma formation
[52–55]
Monocyte IL-10 production [70]
B cell Proliferation, Ig production [58–64]
T cell HLA-DR and CD25 expression, GM-CSF production [19]
NK cell Enhancement of cytotoxic activity [65]
Endothelial cell Cell death, induction of pro-coagulant agents,
adhesion molecules and pro-inflammatory cytokines
[42, 19, 56, 57]
Adipose tissue Inhibition of adipocyte differentiation,
local insulin resistance
[66, 67]
Heart Concentric cardiac hypertrophy [68, 69]
Lung Interstitial inflammation [36, 37]
Liver Hepatitis [40, 41]
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Transmembrane TNF-aTNF-a [45]. By using transmembrane TNF-a-knock-in
mice, which express functional transmembrane TNF-a
but do not release soluble TNF-a, transmembrane TNF-a
was shown to be sufficient to control infection due to
L. major [46]. In vitro tissue co-culture system revealed
that T-cell-expressed transmembrane TNF-a is necessary
and sufficient for memory T-cell responses to intracellular
pathogen Francisella tularensis, and is particularly impor-
tant for intramacrophage control of bacterial growth by
CD8
+ T cells [47]. IFN-g induces monocyte apoptosis
and Coxiella burnetii killing through b2-integrin-mediated
cell clustering, which allows transmembrane TNF-a
to deliver a death signal to infected monocytes. Both
TNF-R1 and -R2 are involved in this process [48].
Transmembrane TNF-a participates in cell-mediated
immunity to Listeria monocytogenes as shown in trans-
genic mice. In the absence of secreted TNF-a, transmem-
brane TNF-a endows macrophages with enhanced
capacity to kill L. monocytogenes [49].
Protective immune response to Mycobacterium tuber-
culosis is regulated by T cells, macrophages and cyto-
kines, such as INF-g, IL-12 and TNF-a [50, 51]. A critical
role of TNF-a has been extensively reported in neutralizing
or gene-deletion experiments in mice infected with myco-
bacterial species with varying virulence. The importance
of transmembrane TNF-a for protection from M. tubercu-
losis or less virulent M. bovis bacillus Calmette–Guerin
infection was demonstrated in transgenic mice expressing
transmembrane TNF-a [52, 53]. Transmembrane TNF-a is
sufficient to initiate T cell and macrophage migration as
well as granuloma formation, and effective against acute,
but not long-term M. tuberculosis infection [54, 55].
Activation of endothelial cells
Human umbilical vein endothelial cells (HUVECs) co-cul-
tured with transmembrane TNF-a-expressing Chinese
hamster ovary (CHO) cells expressed tissue factor with
synergistic action of both TNF-R1 and -R2 in an adhe-
sion molecule (E-selectin/ICAM-1)-dependent manner
[19, 56]. In addition, plasma membranes isolated from
stimulated T lymphocytes up-regulated the expression
of ICAM-1, vascular cell adhesion molecule-1 (VCAM-1)
and E-selectin on isolated human brain microvascular
endothelial cells (HB-MEC) and their IL-6 expression
[57], which was partly diminished by inhibitors of TNF-a.
Induction of pro-coagulant agents, adhesion molecules
and pro-inflammatory cytokine by transmembrane TNF-a
may reflect the inflammation of microvessels mediated by
direct cell-to-cell contact between inflammatory cells and
endothelial cells.
B-cell proliferation and immunoglobulin production
Transmembrane TNF-a is expressed on HIV-infected
CD4
+ T cells and markedly stimulated proliferation and
immunoglobulin (Ig) production by both autologous
and allogeneic B cells in an antigen-non-specific,
MHC-unrestricted, contact-dependent manner [58, 59].
Likewise, B-cell activation was induced by transmem-
brane TNF-a on HTLV type I (HTLV-I)-infected CD4
+
T cells and herpesvirus saimiri-transformed CD4
+ T cells
[60–62]. It is thus considered that human CD4
+ T-cell
clones, when infected by certain viruses, can provide
abnormal B cell help and explain at least in part the hyper-
gammaglobulinaemia and other phenomena related to
polyclonal B-cell activation seen in patients infected with
these viruses [63]. In healthy individuals, transmembrane
TNF-a on Con A-activated CD4
+ T-cell clones provided a
co-stimulatory signal for human B-cell activation and Ig
production through TNF-R1, but not by TNF-R2 [64].
T-cell/thymocyte activation
Transmembrane TNF-a expressed on CHO cells stimu-
lated human peripheral T cells to express HLA-DR [19].
Thymocytes from TNF-R2 transgenic mice induced prolif-
eration, CD25 expression and GM-CSF production when
co-cultured with transmembrane TNF-a-expressing
CHO cells [19].
NK cell stimulation
Transmembrane TNF-a is an important mediator for NK
cell–dendritic cell (DC) crosstalk [65]. In mouse, prolifera-
tion and cytotoxic activity of NK cells were enhanced by
transmembrane TNF-a on DCs through NK cell-surface
TNF-R2.
Adipocyte differentiation
Expression of transmembrane TNF-a on adipocytes
resulted in inhibition of differentiation by selectively
activating TNF-R1 [66]. This result might indicate that
transmembrane TNF-a is a local mediator of insulin resis-
tance. Supporting evidence was demonstrated in trans-
genic mice. Mice specifically expressing transmembrane
TNF-a in adipocytes showed a decreased whole body
adipose mass, and local, but not systemic, insulin resis-
tance [67]. These data demonstrate that exclusive action
of TNF-a in adipose tissue strongly inhibits insulin action
at this site and leads to reduced adiposity in mice.
Cardiac hypertrophy
There is a growing body of evidence that the short-term
and self-limited expression of TNF-a plays an important
homeostatic role in the heart [68]. Transgenic mice
with cardiac-restricted overexpression of transmembrane
TNF-a provoke a concentric hypertrophic cardiac
phenotype [69].
Cytokine production from monocytes
Transmembrane TNF-a expressed on glutaraldehyde-
fixed pre-stimulated human T-cells induced monocytes
to secrete IL-10 in a cell–cell contact manner [70].
TNF-R1 and -R2 on the monocyte surface are stimulated
by transmembrane TNF-a on glutaraldehyde-fixed
pre-stimulated human CD4
+ T cells to produce TNF-a.
Extracellular signal-regulated kinase, a member of mito-
gen-activated protein kinases, was involved in the down-
stream signalling [71]. It is thus considered that
transmembrane TNF-a plays an important role for
1218 www.rheumatology.oxfordjournals.org
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nate interaction.
Biological activities of transmembrane
TNF-a as a receptor
Transmembrane TNF-a-bearing cells show their biological
activity when transmembrane TNF-a on their cell surface
is bound to its receptor, TNF-R1 or -R2. The biological
activity is induced by the transmembrane TNF-a-
mediated signal, also called an ‘outside-to-inside signal’
or ‘reverse signal’. In contrast to the well-characterized
functions of transmembrane TNF-a as a ligand, the bio-
logical functions elicited by outside-to-inside (reverse)
signal have not completely been clarified. However, it is
supposed that outside-to-inside signalling mediated by
transmembrane TNF-a contributes to the pleiotropy of
this pro-inflammatory cytokine and its fine-tuning of
immune response [6]. The biological activities of trans-
membrane TNF-a as a receptor have been demonstrated
in T cells, monocytes/macrophages and NK cells in
humans [72–76]. The elevation of intracellular calcium
concentration in both human T-cell line and mouse
macrophage cell line [62, 77] was induced through trans-
membrane TNF-a (Table 2).
Modulation ofT-cell function
Harashima et al. [72] reported that activation by polyclonal
anti-TNF-a antibody against transmembrane TNF-a on
phytohemagglutinin-activated normal human CD4
+ T
cells resulted in the induction of an adhesion molecule,
E-selectin (CD62E). In addition, Jurkat T cells or HeLa
cells stably expressing transmembrane TNF-a up-
regulated E-selectin when brought into cell-to-cell contact
with TNF-R2-expressing HeLa cells [72]. Transmembrane
TNF-a was involved in the alloresponse of T cells against
human microvascular endothelial cells (HMECs) [73].
CD4
+ T cells proliferated upon stimulation with HMECs
were down-regulated by reverse signalling through trans-
membrane TNF-a. In addition, stimulation of transmem-
brane TNF-a on CD8
+ T cells increased their cytotoxic
potential against HMECs, although the stimulation was
not by native cell-surface TNF-R, but by polyclonal
anti-TNF-a or soluble TNF-R production of IL-2 and
IFN-g in human T-cell line [62].
Modulation ofmonocyte/macrophage function
In human monocytes/macrophages pre-incubated with
TNF-R1-expressing human endothelial cells, reverse sig-
nalling through transmembrane TNF-a mediated LPS
resistance as indicated by the down-regulation of
LPS-induced soluble TNF-a and IL-6 as well as IL-1 and
-10 [74]. Pre-treatment with soluble TNF-R1 for inducing
reverse signalling through transmembrane TNF-a sensi-
tized human monocyte cell line U937 cells to soluble
TNF-a-induced activation, whereas stimulation of trans-
membrane TNF-a after soluble TNF-a-induced activation
of U937 cells reduced mRNA stability of IL-1b and IL-8
[75]. In contrast to these findings that transmembrane
TNF-a may inhibit sustained activation of monocytes,
transmembrane TNF-a played a positive role in the acti-
vation of monocytes. Ligation of transmembrane TNF-a
on monocytes by TNF-R2 on T cells or soluble
TNF-R2:Ig receptor construct (etanercept) induced
TNF-a production due to outside-to-inside signalling
through transmembrane TNF-a [71].
Activation of NKcell function
Such a positive effect by transmembrane TNF-a was also
reported in NK cells. Pre-stimulation of transmembrane
TNF-a with soluble TNF-R1 resulted in increased cytotoxi-
city of NK92 cells, a human NK cell line [76]. This
increased cytotoxicity of NK92 cells was accompanied
by augmented mRNA production of two cytotoxic mole-
cules, perforin and granzyme B.
OtherTNFligand familymembersandoutside-to-inside
signal
These lines of evidence indicate that transmembrane
TNF-a transmits outside-to-inside signals back to the
cell by a cell-to-cell contact manner in local inflammation.
Outside-to-inside (reverse) signals transmitted by other
members of TNF ligand family have also been reported.
CD40L co-stimulation is important in the regulation of IL-4
production from T cells [78]. CD30L on the neutrophil
transmits reverse signal to induce IL-8 expression and a
Table 2 Biological activities of transmembrane TNF-a as a receptor
tmTNF-expressing
cells Function Reference
T cell E-selectin expression, [72]
Production of IL-2 and IFN-g [62]
Alloresponse against endothelial cells [73]
Monocyte/macrophage Down-regulation of LPS-induced soluble TNF-a, IL-6, IL-1 and IL-10 [74]
Sensitization to soluble TNF-induced activation (pre-stimulation) or
reduction of mRNA stability of IL-1b and IL-8 (post-stimulation)
[75]
TNF-a production [71]
NK cell Increased cytotoxicity by up-regulation of perforin and granzyme B [76]
tmTNF: transmembrane TNF-a.
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Transmembrane TNF-arapid respiratory burst [79]. In addition, outside-to-inside
signal transmitted by CD27L or FasL leads to T-cell pro-
liferation [80–82]. Enhancement of IgG production of B
cells and promotion of maturation of DCs were shown to
be reverse signalling by OX40L [83]. Outside-to-inside sig-
nals have been studied relatively well for the CD137L. A
variety of biological functions, such as cytokine induction
and cell proliferation, in different cell types have been
reviewed recently [84].
Binding of anti-TNF agents to soluble
and transmembrane TNF-a
Anti-TNF agents have been successfully applied to
the treatment of Crohn’s disease and RA as well as
other chronic inflammatory diseases like psoriasis, AS
and Behc ¸et’s disease [1, 85]. Three anti-TNF agents,
infliximab, adalimumab and etanercept, are approved
worldwide for the treatment of these diseases and there
are ample data on the clinical profile. Other anti-TNF
agents, certolizumab pegol and golimumab, have just
been approved for clinical use. Infliximab, adalimumab
and golimumab are mAbs against human TNF-a and eta-
nercept is engineered from human TNF receptors (Fig. 2).
Infliximab is a chimeric mouse–human anti-TNF-a mAb
composed of a murine variable region and a human
IgG1 constant region. Adalimumab and golimumab are
fully humanized anti-TNF-a mAbs, which are indistinguish-
able from the normal human IgG1. Etanercept is
composed of the extracellular portion of the two human
TNF-R2 (p75 TNF receptor) linked to the Fc portion (CH2
and CH3 domains) of human IgG1. Certolizumab is a Fab’
fragment of an anti-TNF-a IgG1 mAb and is lacking the Fc
portion. The hinge region of certolizumab is covalently
linked to two cross-linked chains of 20kDa of polyethyl-
ene glycol, giving certolizumab pegol [86].
Infliximab binds to both monomer and trimer forms of
soluble TNF-a, whereas etanercept binds only to the
trimer form [87]. Infliximab formed stable complexes
with soluble TNF-a, while etanercept formed relatively
unstable complexes [87]. Each infliximab molecule is
capable of binding to two TNF-a molecules, and up to
three infliximab molecules can bind to each TNF-a homo-
trimer. In contrast, etanercept is supposed to form 1:1
complex with the TNF-a trimer [87]. In fact, the mAbs,
but not TNF-R2:Ig soluble receptor, form large protein
complexes in vitro [88]. Overall, all three anti-TNF agents
have similar intrinsic binding properties for soluble TNF
[10]. Although these kinds of analysis at the molecular
level have not been performed, certolizumab pegol
showed similar potency in neutralizing soluble TNF-a to
infliximab, adalimumab and etanercept [89].
Infliximab, adalimumab, etanercept and certolizumab
pegol bind to transmembrane TNF-a on transmembrane
TNF-a-transfected cells [7, 9, 89] with similar affinities
that were lower (weaker) than for soluble TNF-a [10].
As in the case of soluble TNF-a, up to three molecules
of infliximab can bind one transmembrane TNF-a, one
etanercept can bind one molecule of transmembrane
TNF-a [87].
Fig. 2 Structures of anti-TNF agents.
Infliximab is a mouse–human chimeric monoclonal anti-TNF antibody of IgG1 isotype. Adalimumab and golimumab are
fully human IgG1 monoclonal anti-TNF antibodies. Etanercept is a fusion protein of the extracellular domain of TNF-R2
and the Fc region of IgG1. Certolizumab pegol is a PEGylated Fab0 fragment of humanized monoclonal anti-TNF
antibody.
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on transmembrane TNF-a
Among the five anti-TNF agents, infliximab, adalimumab
and etanercept are approved and have been clinically
introduced worldwide for years. Here, we would like to
describe the functional properties of anti-TNF agents
with emphasis on these three widely used TNF antago-
nists. Infliximab, adalimumab and etanercept are effective
for the treatment of RA, PsA and AS; however, etanercept
is not effective for Crohn’s disease, Wegener’s granulo-
matosis and sarcoidosis [86, 90]. This difference in the
clinical efficacy may be explained by the differences in
pharmacokinetics, tissue distribution and functional prop-
erties of these anti-TNF agents. Considering the important
role of transmembrane TNF-a in health and diseases, dif-
ferential effects of anti-TNF agents on transmembrane
TNF-a may explain the difference in these clinical effica-
cies. A number of groups have reported head-to-head
comparison of the functional properties for these
anti-TNF agents on transmembrane TNF-a [7, 8, 10, 87,
89] (Fig. 3).
Inhibition of ligand activity of transmembrane TNF-a
Infliximab was significantly more potent than etanercept
at blocking transmembrane TNF-a-mediated E-selectin
expression in HUVECs [87]. In a bioassay using human
lung carcinoma cell line A549, infliximab, adalimumab
and certolizumab pegol similarly inhibited transmembrane
TNF-a-mediated cell death; however, etanercept showed
 2-fold less activity [89]. Taken together, effector function
of transmembrane TNF-a is inhibited by any of the
anti-TNF agents, although the activity of etanercept is
weaker than the other antagonists.
Inhibition of transmembrane TNF-a-bearing cells
Complement-dependent cytotoxicity. In a system using
human Jurkat T cells [8], mouse NS0 myeloma cells [89],
mouse Sp2/0 myeloma cells [10] or CHO cells [9],
complement-dependent cytotoxicity (CDC) was analysed
for the anti-TNF agents. All the reports were in agreement
that infliximab and adalimumab induced CDC much more
potently than etanercept. In contrast, certolizumab pegol
did not have any CDC activity [89], which reflects its
absence of the Fc portion of IgG1. From the structural
point of view, lack of activation of the complement
system by etanercept seems to be reasonable as well.
Infliximab, adalimumab and etanercept commonly pos-
sess the Fc portion of IgG1, whose CH2 domain activates
the first component of complement (C1) activation (Fig. 4).
However, etanercept does not carry the CH1 domain of
IgG1. A narrow region of 23 amino acid residues within the
CH1 domain serves as a platform for complement C3 acti-
vation [91]; it was later confirmed that three amino acid
residues within the specific 23 amino acids are involved in
the covalent attachment with C3 [92, 93]. Etanercept is
Fig. 3 Inhibition of TNF-a-bearing cells by anti-TNF agents.
Transmembrane TNF-a plays an important role in granuloma formation, which is essential for the development of
granulomatous diseases such as Crohn’s disease, and the host defence against tuberculosis. There are at least four
distinct mechanisms for the inhibition of TNF-a-bearing cells by anti-TNF agents: (i) inhibition of transmembrane
TNF-a-mediated effector function, (ii) destruction of TNF-a-bearing cells by CDC, (iii) destruction of TNF-a-bearing cells
by ADCC and (iv) destruction of TNF-a-bearing cells by outside-to-inside signal (reverse signal).
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Transmembrane TNF-astructurally impaired in the appropriate activation of C3,
the most important step in complement activation.
Moreover, lack of a hinge region in the Fc portion of eta-
nercept resulted in rigidity compared with the natural anti-
body and eventually culminated in conformational
hindrance to the proper access of complement proteins.
It is thus difficult for etanercet to make a membrane
attack complex of complement proteins (C5b–C9) for
CDC at least in vitro. When activated human peripheral
blood mononuclear cells were studied as target cells,
none of these three anti-TNF agents induced CDC [10],
which may be due to the use of different cell types from
the above-mentioned experiments.
Antibody-dependent cell-mediated cytotoxicity. Infliximab,
adalimumab and etanercept showed similar antibody-
dependent cell-mediated cytotoxicity (ADCC) activitiy
using mTNF-transfected Jurkat T cells as target [8],
while infliximab and adalimumab showed much more
potent ADCC than etanercept in NS0 cells [89] or in CHO
cells [9]. Certolizumab pegol did not show any ADCC
activity [89]. The discrepancy in etanercept-induced
ADCC is not clear, but may be explained by the different
experimental conditions, such as difference in the species
of target cell, in the expression level of transmembrane
TNF-a. From the structural viewpoint, infliximab, adalimu-
mab and etanercept carry CH2 and CH3 domains of the Fc
domain of IgG1, whereas certolizumab pegol does not
(Fig. 4). These domains of IgG1 are involved in the binding
to Fc receptors of NK cells [94], which leads to the lysis of
target cells by granzyme B and perforin. The presence or
absence of soluble TNF-a in the assay system may also
affect ADCC activities. Both mAbs and etanercept weakly
bound to Fcg receptors in the absence of soluble TNF-a,
but in the presence of soluble TNF-a, there was a marked
increase in binding only by mAbs infliximab and
adalimumab [9]. As for infliximab, induction of both CDC
and ADCC has been reported by others [95].
Outside-to-inside signalling (reverse signalling). This is a
novel function of anti-TNF agents for the inhibition of
TNF-a-producing cells, which is mediated by mechanisms
independent of CDC and ADCC [8, 96] (Fig. 5). Infliximab
and adalimumab, but not etanercept, induced apoptosis
and cell cycle G0/G1 arrest upon binding to transmem-
brane TNF-a-expressing Jurkat T cells. Cross-linking of
etanercept bound to the cell-surface transmembrane
TNF-a resulted in increased apoptosis [96], which
indicates that multimer formation with mAbs and trans-
membrane TNF-a may be essential for the initiation
of the subsequent intracellular signals. IL-10 production
was induced by infliximab, but not by etanercept, in trans-
membrane TNF-alpha-expressing Jurkat T cells [96].
c-Jun NH2-terminal kinase activation followed by
Fig. 4 CDC and ADCC by anti-TNF agents.
Infliximab, adalimumab and etanercept commonly possess the Fc portion of IgG1, whose CH2 domain activates com-
plement C1. Activation of C1 leads to complement C3 activation and subsequent formation of a membrane attack
complex (C5b–C9) and lysis of the target cells. However, etanercept does not carry the CH1 domain of IgG1 which is
important for the activation of C3. Infliximab, adalimumab and etanercept carry CH2 and CH3 domains of the Fc domain
of IgG1 that mediate the binding to Fc receptors, which culminates in granzyme B and perforin release from NK cells and
lysis of the target cells.
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This is a novel mechanism for the inhibition of transmembrane TNF-a-bearing cells by anti-TNF antibodies. In the
absence of NK cells or complement, adalimumab or infliximab induces G0/G1 cell cycle arrest and apoptosis, which
inhibits TNF-a-producing cells and leads to an anti-inflammatory response. A number of molecules (p21
WAF1/CIP1, Bax,
Bak and ROS) were involved in these intracellular signalling events through the intracellular domain of transmembrane
TNF-a. These signalling molecules are supposed to be associated with p53 activation. Three serine residues in the
intracellular domain of transmembrane TNF-a are essential for the activities. Bak and Bax are proapoptotic multidomain
molecules; tmTNF: transmembrane TNF-a.
Fig. 6 Structure of transmembrane TNF-a.
Transmembrane TNF-a is a type II polypeptide composed of a extracellular domain (177 amino acid residues), a
transmembrane domain (26 amino acid residues, shaded) and an intracellular domain (30 amino acid residues). Mature
TNF-a (soluble TNF-a) of 157 amino acid residues is cleaved from transmembrane TNF-a by TACE (black arrow). The
remaining part is further cleaved by SPPL2b in the transmembrane domain (two grey arrows), and the intracellular domain
is translocated into the nucleus to possibly modulate gene expression of the TNF-a-bearing cells. The intracellular
domain contains CKI motif (boxed) and three serine residues. These serine residues are conserved among different
species and are essential for the outside-to-inside signal transmitted by transmembrane TNF-a upon binding to anti-TNF
antibody. Amino acid residues are shown in the one-letter code. The transmembrane domain of transmembrane TNF-a is
shaded.
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WAF1/CIP1, Bax and Bak as well as
reactive oxygen species (ROS) accumulation are impor-
tant intracellular signalling events for apoptosis and cell
cycle arrest [96]. In addition, site-directed mutagenesis
revealed that three serine residues in the cytoplasmic
domain of transmembrane TNF-a are essential for these
biological effects. The amino acid sequence of the intra-
cellular domain of transmembrane TNF-a is well con-
served in different species [77] (Fig. 6), and is thus
considered to play an important role. All three serine res-
idues were conserved among different species. A casein
kinase I (CKI) consensus sequence in the cytoplasmic
domain may be involved in outside-to-inside signalling
as well [77]. This domain is dephosphorylated upon acti-
vation of transmembrane TNF-a in mouse macrophage
cell line RAW264.7, and is accompanied by an increase
in intracellular calcium levels [77]. Increase in intracellular
calcium levels by outside-to-inside signal of transmem-
brane TNF-a has also been reported by others [62]. For
the outside-to-inside signalling, the amino-terminal intra-
cellular domain of transmembrane TNF-a cleaved by
signal peptide peptidase-like 2b (SPPL2b) may play an
additional role [97, 98]. This cleaved intracellular domain
triggers expression of the pro-inflammatory cytokine IL-12
in human DCs [97]. Consistent with these findings, the
amino-terminal intracellular domain of transmembrane
TNF-a contains a putative nuclear localizing signal
(KKTGGPQGSRR; one-letter amino acid code), localizes
in the nucleus and seems to be associated with IL-1b
expression in human HeLa cells [22, 99].
Granulomatous diseases and
transmembraneTNF-a
The three widely used anti-TNF agents, infliximab, adali-
mumab and etanercept, show different clinical efficacy.
Infliximab and adalimumab, but not etanercept, are effec-
tive against such diseases as Crohn’s disease, WG
and sarcoidosis [86, 90]. These are granulomatous inflam-
matory disorders. In addition, side effects are differ-
ent between these anti-TNF agents. Post-marketing
surveillance in the USA (from January 1998 through
September 2002) has identified that infliximab was
associated with a 2- to 8-fold greater risk of such granu-
lomatous infections as tuberculosis, listeriosis and histo-
plasmosis compared with etanercept [100]. The increased
incidence of tuberculosis in patients treated with inflixi-
mab or adalimumab compared with etanercept was also
reported in other European countries [101]. It has become
apparent that efficacy in granulomatous inflammatory dis-
eases and risk of granulomatous infections seems to
reflect the anti-granuloma function of anti-TNF agents. In
fact, specimens from RA patients who developed tuber-
culosis after treatment with infliximab lack granuloma for-
mation [102]. The presence or absence of an
anti-granuloma effect would be the most prominent differ-
ence between the currently available anti-TNF agents.
Transmembrane TNF-a has recently been shown to con-
tribute to the host defence against acute M. tuberculosis
infection in humans. CD8
+CCR7-CD45RA
+ effector
memory T cells express granulysin and mediate anti-
microbial activity against M. tuberculosis [103]. This
T-cell subset expressed transmembrane TNF-a
and bound infliximab, making itself susceptible to
complement-mediated lysis and the resultant reduced
antimicrobial activity.
In patients with Crohn’s disease, treatment with inflix-
imab induced a rapid increase of the number of apoptotic
CD3
+ lamina propria T cells, without detectable changes
in peripheral blood T lymphocyte phenotype or markers of
apoptosis [104]. Moreover, transmembrane TNF-a, in the
absence of soluble TNF-a, induces colitis in a mouse
model [105]. In the clinical setting, it is likely that infliximab
induces apoptosis at least in part by transmembrane TNF-
a-mediated effects: CDC, ADCC and/or outside-to-inside
signalling.
Considering that infliximab and adalimumab induce
CDC, ADCC and outside-to-inside signalling through
transmembrane TNF-a, these anti-TNF mAbs seem
to be more potent than etanercept in the elimination of
transmembrane TNF-a-bearing macrophages and trans-
membrane TNF-a-bearing T cells. Thus, infliximab and
adalimumab may more strongly inhibit granuloma forma-
tion by these cells in tuberculosis or in Crohn’s disease, as
compared with etanercept. Different effects of these
anti-TNF agents on transmembrane TNF-a might at least
partly explain their different clinical efficacies. Although
available information is limited for the new anti-TNF
agents, certolizumab pegol and golimumab, it is important
to further analyse both the basic and clinical data of these
new agents and put the pieces together to more precisely
understand the similarities and dissimilarities of mechan-
ism of action of anti-TNF agents. Moreover, it is of note
that the clinical efficacy profiles are not solely dependent
on the mode of action on transmembrane TNF-a. These
anti-TNF agents are not similar with respect to doses,
routes and frequency of administration, pharmacokinetics
or immunogenicity. There might be other indirect effects in
the inflammatory network different between the anti-TNF
agents. The mechanisms of action of these anti-TNF
agents are more complex in patients than in in vitro
experiments.
Conclusion
Transmembrane TNF-a is a bipolar molecule that trans-
mits signals as a ligand and as a receptor back to the cell.
It is thus considered that transmembrane TNF-a plays
an important role in local inflammation in a cell-to-cell
contact manner. Infliximab, adalimumab and etanercept
similarly bind to transmembrane TNF-a on TNF-a-
producing cells, and the former two mAbs seem to trans-
mit stronger inhibitory signals through transmembrane
TNF-a. Understanding the mechanism of action of
anti-TNF agents and their relationship with clinical effects
will contribute to appropriate prediction of the clinical effi-
cacy of forthcoming anti-TNF agents, the application of
the agents to new disease targets and the development
of new anti-TNF agents.
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. Transmembrane TNF-a, a precursor form of soluble
TNF-a, transmits signals both as a ligand and as a
receptor.
. Differential clinical efficacies of anti-TNF agents
may be explained by their different action on trans-
membrane TNF-a-bearing cells.
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